Fax: (412) 641-5417
A Gynecologic Oncology Group study
Version of Record online: 20 JAN 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 5, pages 1028–1035, 1 March 2009
How to Cite
Zorn, K. K., Tian, C., McGuire, W. P., Hoskins, W. J., Markman, M., Muggia, F. M., Rose, P. G., Ozols, R. F., Spriggs, D. and Armstrong, D. K. (2009), The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma . Cancer, 115: 1028–1035. doi: 10.1002/cncr.24084
The following Gynecologic Oncology Group member institutions participated in the primary treatment studies: University of Alabama at Birmingham; Oregon Health Sciences University; Duke University Medical Center; Abington Memorial Hospital; University of Rochester Medical Center; Walter Reed Medical Center; Wayne State University; University of Minnesota Medical School; University of Southern California at Los Angeles; University of Mississippi Medical Center; Colorado Gynecologic Oncology Group, PC; University of California at Los Angeles; University of Miami School of Medicine; Milton S. Hershey Medical Center; Georgetown University Hospital; University of Cincinnati; University of North Carolina School of Medicine; University of Iowa Hospitals and Clinics; University of Texas Southwestern Medical Center at Dallas; Indiana University Medical Center; Wake Forest University School of Medicine; Albany Medical Center; University of California Medical Center at Irvine; Tufts-New England Medical Center; Rush-Presbyterian-St. Luke's Medical Center; Stanford University Medical Center; State University of New York Downstate Medical Center; University of Kentucky; Eastern Virginia Medical School; The Cleveland Clinic Foundation; Johns Hopkins Cancer Center; State University of New York at Stony Brook; Eastern Pennsylvania Gynecology/Oncology Center, PC; Washington University School of Medicine; Cooper Hospital/University Medical Center; Columbus Cancer Council; the University of Texas M. D. Anderson Cancer Center; University of Massachusetts Medical School; Fox Chase Cancer Center; Medical University of South Carolina; and Women's Cancer Center, University of Oklahoma.
Abbreviated results of this study were presented in abstract form at the Annual Meeting of the Society of Gynecologic Oncology, San Diego, California, March 3-7, 2007.
We thank Dr. M. J. Krohn who assisted with the development of the initial concept for this project.
- Issue online: 18 FEB 2009
- Version of Record online: 20 JAN 2009
- Manuscript Accepted: 20 AUG 2008
- Manuscript Revised: 11 AUG 2008
- Manuscript Received: 19 MAY 2008
- National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office. Grant Number: CA-27469
- Gynecologic Oncology Group Statistical Office. Grant Number: CA-37517
- 6Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 1001-1007., , , et al.
- 10A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 449. Abstract 5004., , , et al.
- 12Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley & Sons; 1999., .